Results 251 to 260 of about 185,548 (298)
Some of the next articles are maybe not open access.
Hematology, 2002
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer +7 more
+7 more sources
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer +7 more
+7 more sources
2007
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of disorders which originate from various important genetic lesions in B and T progenitor cells, including mutations that lead to stage-specific developmental arrest and those that impart the capacity for unlimited self-renewal, resulting in clonal expansion of immature progenitor cells
Biondi A., Scrideli C. A., Cazzaniga G.
+5 more sources
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of disorders which originate from various important genetic lesions in B and T progenitor cells, including mutations that lead to stage-specific developmental arrest and those that impart the capacity for unlimited self-renewal, resulting in clonal expansion of immature progenitor cells
Biondi A., Scrideli C. A., Cazzaniga G.
+5 more sources
Clinics in Laboratory Medicine, 2000
Over the last two decades, great strides have been made in the treatment of acute lymphoblastic leukemia (ALL). This progress has been paralleled by advances in diagnosis. In addition to morphology and cytochemistry, the diagnostic and prognostic importance of immunophenotypic and genetic features is becoming increasingly apparent. This article reviews
D C, Farhi, N S, Rosenthal
openaire +2 more sources
Over the last two decades, great strides have been made in the treatment of acute lymphoblastic leukemia (ALL). This progress has been paralleled by advances in diagnosis. In addition to morphology and cytochemistry, the diagnostic and prognostic importance of immunophenotypic and genetic features is becoming increasingly apparent. This article reviews
D C, Farhi, N S, Rosenthal
openaire +2 more sources
Pediatric Clinics of North America, 1997
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +3 more sources
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +3 more sources
Neonatal Acute Lymphoblastic Leukemia
Pediatric Emergency Care, 2020Abstract Acute lymphoblastic leukemia (ALL) in a neonate can have a similar clinical appearance to other serious pathology and should be considered in the ill-appearing infant. We present the case of a 24-hour-old male infant born to a mother with limited prenatal care who was brought to the pediatric emergency department with a rash and ...
Rachel, Oliver +4 more
openaire +2 more sources
Childhood acute lymphoblastic leukemia
Reviews in Clinical and Experimental Hematology, 2002As cure rates in childhood acute lymphoblastic leukemia reach 80%, emphasis is increasingly placed on the accurate identification of drug‐resistant cases, the elucidation of the mechanisms involved in drug resistance and the development of new therapeutic strategies targeted toward the pivotal molecular lesions.
Ching-Hon, Pui +3 more
openaire +2 more sources
Acute lymphoblastic leukemia: Treatment
Cancer, 1978Over the past thirty years, major progress has been achieved in the treatment of ALL. Many of the concepts, definitions, and principles of chemotherapy have and continue to be derived from studies in ALL. Major and continuing progress is ongoing for the various categories of treatment; that is, remission induction, treatment at sites of high risk for ...
E, Frei, S E, Sallan
openaire +2 more sources
Clinics in Laboratory Medicine, 1999
This article reviews the laboratory methodologies used to evaluate acute lymphoblastic leukemia (ALL) in children and their role in establishing a diagnosis and prognosis of this disease. These methodologies are: morphology, flow cytometry, cytogenetics, and molecular diagnostics.
openaire +2 more sources
This article reviews the laboratory methodologies used to evaluate acute lymphoblastic leukemia (ALL) in children and their role in establishing a diagnosis and prognosis of this disease. These methodologies are: morphology, flow cytometry, cytogenetics, and molecular diagnostics.
openaire +2 more sources
Childhood Acute Lymphoblastic Leukemia
Pediatric Annals, 1988Acute lymphoblastic leukemia accounts for 80% of leukemia in children. The exact cause is unknown, but some genetic, immunologic, viral, and environmental factors have been implicated. Symptoms at the time of diagnosis frequently include fever, bleeding, fatigue, and irritability. Initial white blood cell count and patient age at diagnosis are the most
C A, Diamond, K K, Matthay
openaire +2 more sources
Granular Acute Lymphoblastic Leukemia
American Journal of Clinical Pathology, 1983Granules in blasts are most typical of acute myeloblastic leukemia. However, there have been scattered reports of patients with acute lymphoblastic leukemia (ALL) that have lymphoblasts with azurophilic cytoplasmic granules. These reports do not describe immunologic markers or cytogenetics.
P, Stein +5 more
openaire +3 more sources